Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Antimicrobial Agents and Chemotherapy
Veronica Rico CaballeroD P Nicolau

Abstract

Combination therapy is an attractive option for the treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections; however, limited data are available on combinations with ceftolozane-tazobactam (C-T). The in vitro pharmacodynamic chemostat model was employed to compare human-simulated exposures of C-T at 3 g every 8 h alone or in combination with amikacin at 25 mg/kg of body weight daily or colistin at 360 mg daily against four MDR P. aeruginosa isolates. C-T alone resulted in 24-h changes in the number of CFU of -0.02 ± 0.21, -1.81 ± 0.55, -1.44 ± 0.40, and +0.62 ± 0.05 log10 CFU/ml against isolates with C-T MICs of 4, 4, 8, and 16 μg/ml, respectively. Amikacin and colistin monotherapy displayed various results. The addition of amikacin to C-T resulted in -2.00 ± 0.23 (P < 0.001, additive)-, -1.50 ± 0.83 (P = 0.687, indifferent)-, -2.84 ± 0.08 (P = 0.079, indifferent)-, and -2.67 ± 0.54 (P < 0.001, synergy)-log10 CFU/ml reductions, respectively. The addition of colistin to C-T resulted in -3.02 ± 0.22 (P < 0.001, additive)-, -3.21 ± 0.24 (P > 0.05, indifferent)-, -4.6 ± 0.11 (P = 0.002, synergy)-, and -3.01 ± 0.28 (P < 0.001, synergy)-log10 CFU/ml reductions, respectively, against the MDR P. aeruginosa isolates wit...Continue Reading

References

Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert A Bonomo, Dora Szabo
Nov 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W BoucherJohn Bartlett
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Arnold LouieG L Drusano
Jan 8, 2014·The Cochrane Database of Systematic Reviews·Mical PaulLeonard Leibovici
Apr 25, 2014·The Journal of Infectious Diseases·George Louis DrusanoArnold Louie
May 30, 2014·The Journal of Antimicrobial Chemotherapy·Mical PaulLeonard Leibovici
Dec 17, 2014·Expert Opinion on Pharmacotherapy·Abrar K ThabitDavid P Nicolau
Nov 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger L NationFernanda P Silveira
Dec 10, 2015·Infectious Diseases and Therapy·Phillip J BergenBrian T Tsuji
Apr 7, 2016·Journal of Chromatographic Science·Christina A Sutherland, David P Nicolau
Jun 19, 2016·Annals of Clinical Microbiology and Antimicrobials·Christina A SutherlandDavid P Nicolau
Jul 13, 2016·Expert Review of Anti-infective Therapy·Matthew E FalagasKonstantinos Z Vardakas
Mar 16, 2017·Journal of Global Antimicrobial Resistance·Richa GuptaAnuradha Singh
Mar 23, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose M MunitaCesar A Arias
Apr 17, 2017·International Journal of Antimicrobial Agents·Aurélien DinhMichel Wolff
Sep 13, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H WrightD L Paterson
Dec 23, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G G RaoA Forrest
Dec 23, 2017·The Journal of Antimicrobial Chemotherapy·Marguerite L Monogue, David P Nicolau

❮ Previous
Next ❯

Citations

Apr 25, 2019·Antibiotics·Justin R LenhardKeith S Kaye
Sep 11, 2019·Current Infectious Disease Reports·Stephanie HoConan MacDougall
Apr 3, 2020·The Journal of Antimicrobial Chemotherapy·Gabriel T CubaCarlos R V Kiffer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.